Cargando…

TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience

BACKGROUND: Hepatocellular carcinoma (HCC) with symptomatic portal hypertension (SPH) has poor prognosis. A transjugular intrahepatic portosystemic shunt (TIPS) relieves SPH, but its application in HCC remains unclear. We evaluated TIPS efficacy in patients with HCC and SPH. METHODS: Pre- and post-T...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Huzheng, Qiu, Zhenkang, Xiang, Zhanwang, Feng, Kai, Huang, Mingsheng, Gao, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858571/
https://www.ncbi.nlm.nih.gov/pubmed/35183265
http://dx.doi.org/10.1186/s40644-022-00451-9
_version_ 1784654269528408064
author Yan, Huzheng
Qiu, Zhenkang
Xiang, Zhanwang
Feng, Kai
Huang, Mingsheng
Gao, Fei
author_facet Yan, Huzheng
Qiu, Zhenkang
Xiang, Zhanwang
Feng, Kai
Huang, Mingsheng
Gao, Fei
author_sort Yan, Huzheng
collection PubMed
description BACKGROUND: Hepatocellular carcinoma (HCC) with symptomatic portal hypertension (SPH) has poor prognosis. A transjugular intrahepatic portosystemic shunt (TIPS) relieves SPH, but its application in HCC remains unclear. We evaluated TIPS efficacy in patients with HCC and SPH. METHODS: Pre- and post-TIPS Child–pugh(C–P) scores and stages in 123 HCC patients with SPH from three centers were compared. The impact of postoperative C–P stage indicators on overall survival (OS) was explored. RESULTS: Post-TIPS responses to SPH included complete response (CR) (92 [74.8%]), partial response (PR) (23 [18.7%]), and nonresponse (NR) (8 [6.5%]). The control (proportion of CR and PR) for SPH was 93.5%. Median C–P scores pre-TIPS and at one month post-TIPS were 8 (IQR 6–9) and 7 (IQR 6–8), respectively (P < 0.001). Forty-one (33.3%) patients had C–P downstaging; 73 (59.3%) had lowered C–P scores; and 73 (59.3%) received intrahepatic local therapy post-TIPS. The median OS was 10.7 (1.1–55.2) months. Among the five indicators of C–P stage, lower post-TIPS ascites grading [(0/1)/(2/3); P = 0.014, HR = 0.31 (95% CI: 0.12–0.79)] and bilirubin [< 34/ ≥ 34 µmol/L; P = 0.022, HR = 0.47 (95% CI: 0.23–0.82)] and prothrombin time prolongation < 6 s [< 6/ ≥ 6 s; P = 0.001, HR = 0.17 (95% CI: 0.06–0.47)] were independent protective indicators of OS. These three indicators were included in the nomogram model to predict survival probabilities. CONCLUSIONS: TIPS is safe and effective for HCC with SPH. This procedure can relieve the symptoms, enable subsequent antitumor therapy, and bring survival benefits, possibly through improved liver function by reducing C–P stage.
format Online
Article
Text
id pubmed-8858571
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88585712022-02-23 TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience Yan, Huzheng Qiu, Zhenkang Xiang, Zhanwang Feng, Kai Huang, Mingsheng Gao, Fei Cancer Imaging Research Article BACKGROUND: Hepatocellular carcinoma (HCC) with symptomatic portal hypertension (SPH) has poor prognosis. A transjugular intrahepatic portosystemic shunt (TIPS) relieves SPH, but its application in HCC remains unclear. We evaluated TIPS efficacy in patients with HCC and SPH. METHODS: Pre- and post-TIPS Child–pugh(C–P) scores and stages in 123 HCC patients with SPH from three centers were compared. The impact of postoperative C–P stage indicators on overall survival (OS) was explored. RESULTS: Post-TIPS responses to SPH included complete response (CR) (92 [74.8%]), partial response (PR) (23 [18.7%]), and nonresponse (NR) (8 [6.5%]). The control (proportion of CR and PR) for SPH was 93.5%. Median C–P scores pre-TIPS and at one month post-TIPS were 8 (IQR 6–9) and 7 (IQR 6–8), respectively (P < 0.001). Forty-one (33.3%) patients had C–P downstaging; 73 (59.3%) had lowered C–P scores; and 73 (59.3%) received intrahepatic local therapy post-TIPS. The median OS was 10.7 (1.1–55.2) months. Among the five indicators of C–P stage, lower post-TIPS ascites grading [(0/1)/(2/3); P = 0.014, HR = 0.31 (95% CI: 0.12–0.79)] and bilirubin [< 34/ ≥ 34 µmol/L; P = 0.022, HR = 0.47 (95% CI: 0.23–0.82)] and prothrombin time prolongation < 6 s [< 6/ ≥ 6 s; P = 0.001, HR = 0.17 (95% CI: 0.06–0.47)] were independent protective indicators of OS. These three indicators were included in the nomogram model to predict survival probabilities. CONCLUSIONS: TIPS is safe and effective for HCC with SPH. This procedure can relieve the symptoms, enable subsequent antitumor therapy, and bring survival benefits, possibly through improved liver function by reducing C–P stage. BioMed Central 2022-02-19 /pmc/articles/PMC8858571/ /pubmed/35183265 http://dx.doi.org/10.1186/s40644-022-00451-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Yan, Huzheng
Qiu, Zhenkang
Xiang, Zhanwang
Feng, Kai
Huang, Mingsheng
Gao, Fei
TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience
title TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience
title_full TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience
title_fullStr TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience
title_full_unstemmed TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience
title_short TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience
title_sort tips improves outcomes in patients with hcc and symptomatic portal hypertension: a multi-institution experience
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858571/
https://www.ncbi.nlm.nih.gov/pubmed/35183265
http://dx.doi.org/10.1186/s40644-022-00451-9
work_keys_str_mv AT yanhuzheng tipsimprovesoutcomesinpatientswithhccandsymptomaticportalhypertensionamultiinstitutionexperience
AT qiuzhenkang tipsimprovesoutcomesinpatientswithhccandsymptomaticportalhypertensionamultiinstitutionexperience
AT xiangzhanwang tipsimprovesoutcomesinpatientswithhccandsymptomaticportalhypertensionamultiinstitutionexperience
AT fengkai tipsimprovesoutcomesinpatientswithhccandsymptomaticportalhypertensionamultiinstitutionexperience
AT huangmingsheng tipsimprovesoutcomesinpatientswithhccandsymptomaticportalhypertensionamultiinstitutionexperience
AT gaofei tipsimprovesoutcomesinpatientswithhccandsymptomaticportalhypertensionamultiinstitutionexperience